Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Angola to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been steadily growing in the country due to various factors.
Customer preferences: Angolan customers prefer bronchodilator drugs that are affordable and easily accessible. They also prefer drugs that have minimal side effects and are effective in treating their respiratory conditions. Due to the high prevalence of respiratory diseases in the country, there is a high demand for these drugs.
Trends in the market: The Bronchodilator Drugs market in Angola has been growing due to an increase in the prevalence of respiratory diseases in the country. The market has also been growing due to an increase in government spending on healthcare. This has led to an increase in the availability of these drugs in hospitals and clinics across the country. The market has also been growing due to an increase in the number of pharmaceutical companies operating in Angola.
Local special circumstances: Angola has a high prevalence of respiratory diseases due to factors such as air pollution, smoking, and poor living conditions. This has led to an increase in the demand for bronchodilator drugs in the country. However, the market for these drugs is highly regulated, and companies must comply with strict regulations to operate in the country.
Underlying macroeconomic factors: Angola is currently undergoing economic reforms to diversify its economy and reduce its dependence on oil. This has led to an increase in government spending on healthcare and an increase in the availability of healthcare services across the country. The government has also been investing in the pharmaceutical industry to improve the availability of essential drugs such as bronchodilator drugs. However, the country still faces challenges such as a lack of infrastructure and a shortage of skilled healthcare professionals.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
